 |
 |
|
|
|  PubMed
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2 October 2001 | Volume 135 Issue 7 | Pages 484-492
Background: Enterococcus species are major nosocomial pathogens and are exhibiting vancomycin resistance with increasing frequency. Previous studies have not resolved whether vancomycin resistance is an independent risk factor for death in patients with invasive disease due to Enterococcus species or whether antibiotic therapy alters the outcome of enterococcal bacteremia.
Objective: To determine whether vancomycin resistance is an independent predictor of death in patients with enterococcal bacteremia and whether appropriate antimicrobial therapy influences outcome.
Design: Prospective observational study.
Setting: Four academic medical centers and a community hospital.
Patients: All patients with enterococcal bacteremia.
Measurements: Demographic characteristics; underlying disease; Acute Physiology and Chronic Health Evaluation (APACHE) II scores; antibiotic therapy, immunosuppression, and procedures before onset; and antibiotic therapy during the ensuing 6 weeks. The major end point was 14-day survival.
Results: Of 398 episodes, 60% were caused by E. faecalis and 37% were caused by E. faecium. Thirty-seven percent of isolates exhibited resistance or intermediate susceptibility to vancomycin. Twenty-two percent of E. faecium isolates showed reduced susceptibility to quinupristin–dalfopristin. Previous vancomycin use (odds ratio [OR], 5.82 [95% CI, 3.20 to 10.58]; P < 0.001), previous corticosteroid use (OR, 2.43 [CI, 1.22 to 4.86]; P = 0.01), and total APACHE II score (OR, 1.06 per unit change [CI, 1.02 to 1.10 per unit change]; P = 0.003) were associated with vancomycin-resistant enterococcal bacteremia. The mortality rate was 19% at 14 days. Hematologic malignancy (OR, 3.83 [CI, 1.56 to 9.39]; P = 0.003), vancomycin resistance (OR, 2.10 [CI, 1.14 to 3.88]; P = 0.02), and APACHE II score (OR, 1.10 per unit change [CI, 1.05 to 1.14 per unit change]; P < 0.001) were associated with 14-day mortality. Among patients with monomicrobial enterococcal bacteremia, receipt of effective antimicrobial therapy within 48 hours independently predicted survival (OR for death, 0.21 [CI, 0.06 to 0.80]; P = 0.02).
Conclusions: Vancomycin resistance is an independent predictor of death from enterococcal bacteremia. Early, effective antimicrobial therapy is associated with a significant improvement in survival.
Author and Article Information
From Veterans Affairs Medical Center–University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois; Wayne State University School of Medicine and John D. Dingell Veterans Affairs Medical Center, Detroit, and William Beaumont Hospital, Royal Oak, Michigan; and New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts.
Acknowledgment: The authors thank Victor L. Yu, MD, for review of the manuscript.
Requests for Single Reprints: Robert R. Muder, MD, Infectious Disease Section, Veterans Affairs Pittsburgh Healthcare System, University Drive C, Pittsburgh, PA 15240.
Current Author Addresses: Dr. Vergis: Division of Infectious Diseases, University of Pittsburgh, Suite 3A, Falk Medical Building, 3601 Fifth Avenue, Pittsburgh, PA 15213.
Dr. Hayden and Ms. Schmitt: Section of Infectious Diseases, Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, 1653 West Congress Parkway, Chicago, IL 60612.
Dr. Chow: Division of Infectious Diseases, Wayne State University School of Medicine, 3990 John R, Detroit, MI 48201.
Dr. Snydman: Division of Infectious Diseases, New England Medical Center, 720 Washington Street, Box 238, Boston, MA 02111.
Dr. Zervos: William Beaumont Hospital, 3601 West 13 Mile Road, Royal Oak, MI 48073.
Dr. Linden: Department of Anesthesiology and Critical Care Medicine, University of Pittsburgh, 614 Scaife Hall, Pittsburgh, PA 15261.
Ms. Wagener and Dr. Muder: Infectious Disease Section, Veterans Affairs Pittsburgh Healthcare System, University Drive C, Pittsburgh, PA 15240.
Author Contributions: Conception and design: M.K. Hayden, J.W. Chow, D.R. Snydman, M.J. Zervos, P.K. Linden, R.R. Muder.
Analysis and interpretation of the data: E.N. Vergis, M.K. Hayden, J.W. Chow, D.R. Snydman, M.J. Zervos, M.M. Wagener, R.R. Muder.
Drafting of the article: E.N. Vergis, D.R. Snydman.
Critical revision of the article for important intellectual content: E.N. Vergis, M.K. Hayden, J.W. Chow, D.R. Snydman, M.J. Zervos, R.R. Muder.
Final approval of the article: E.N. Vergis, M.K. Hayden, J.W. Chow, D.R. Snydman, M.J. Zervos, P.K. Linden, M.M. Wagener, R.R. Muder.
Provision of study materials or patients: E.N. Vergis, M.K. Hayden, J.W. Chow, D.R. Snydman, M.J. Zervos, P.K. Linden, B.A. Schmitt.
Statistical expertise: M.M. Wagener.
Administrative, technical, or logistic support: M.J. Zervos, P.K. Linden, B.A. Schmitt, R.R. Muder.
Collection and assembly of data: E.N. Vergis, J.W. Chow, D.R. Snydman, M.J. Zervos, M.M. Wagener, B.A. Schmitt. ARTICLE
Determinants of Vancomycin Resistance and Mortality Rates in Enterococcal Bacteremia: A Prospective Multicenter Study
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  G. A. McKay, S. Beaulieu, F. F. Arhin, A. Belley, I. Sarmiento, T. Parr Jr, and G. Moeck Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium J. Antimicrob. Chemother., June 1, 2009; 63(6): 1191 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. McBride, P. S. Coburn, A. S. Baghdayan, R. J. L. Willems, M. J. Grande, N. Shankar, and M. S. Gilmore Genetic Variation and Evolution of the Pathogenicity Island of Enterococcus faecalis J. Bacteriol., May 15, 2009; 191(10): 3392 - 3402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. MacGowan and on behalf of the BSAC Working Parties on Resistanc Clinical implications of antimicrobial resistance for therapy J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii105 - ii114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. N. Forrest, M.-C. Roghmann, L. S. Toombs, J. K. Johnson, E. Weekes, D. P. Lincalis, and R. A. Venezia Peptide Nucleic Acid Fluorescent In Situ Hybridization for Hospital-Acquired Enterococcal Bacteremia: Delivering Earlier Effective Antimicrobial Therapy Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3558 - 3563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-J. Chen, H.-M. Tseng, Y.-L. Huang, W.-N. Hsu, K.-W. Yeh, T.-L. Wu, L.-C. See, and J.-L. Huang Long-term outcome and short-term survival of patients with systemic lupus erythematosus after bacteraemia episodes: 6-yr follow-up Rheumatology, September 1, 2008; 47(9): 1352 - 1357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lautenbach and R. E. Polk Resistant gram-negative bacilli: A neglected healthcare crisis? Am. J. Health Syst. Pharm., December 1, 2007; 64(23_Supplement_14): S3 - S21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Peralta, M. B. Sanchez, J. C. Garrido, I. De Benito, M. E. Cano, L. Martinez-Martinez, and M. P. Roiz Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia J. Antimicrob. Chemother., October 1, 2007; 60(4): 855 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Fletcher, D. Sofianos, M. B. Berkes, and W. T. Obremskey Prevention of Perioperative Infection J. Bone Joint Surg. Am., July 1, 2007; 89(7): 1605 - 1618. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Singh, R. V. Goering, S. Simjee, S. L. Foley, and M. J. Zervos Application of Molecular Techniques to the Study of Hospital Infection Clin. Microbiol. Rev., July 1, 2006; 19(3): 512 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hershberger, S. F. Oprea, S. M. Donabedian, M. Perri, P. Bozigar, P. Bartlett, and M. J. Zervos Epidemiology of antimicrobial resistance in enterococci of animal origin J. Antimicrob. Chemother., January 1, 2005; 55(1): 127 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Sloan, J. R. Uhl, E. A. Vetter, C. D. Schleck, W. S. Harmsen, J. Manahan, R. L. Thompson, J. E. Rosenblatt, and F. R. Cockerill III Comparison of the Roche LightCycler vanA/vanB Detection Assay and Culture for Detection of Vancomycin-Resistant Enterococci from Perianal Swabs J. Clin. Microbiol., June 1, 2004; 42(6): 2636 - 2643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Oprea, N. Zaidi, S. M. Donabedian, M. Balasubramaniam, E. Hershberger, and M. J. Zervos Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis J. Antimicrob. Chemother., April 1, 2004; 53(4): 626 - 630. [Abstract] [Full Text] [PDF]
|
|
